IN2014MN01819A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01819A
IN2014MN01819A IN1819MUN2014A IN2014MN01819A IN 2014MN01819 A IN2014MN01819 A IN 2014MN01819A IN 1819MUN2014 A IN1819MUN2014 A IN 1819MUN2014A IN 2014MN01819 A IN2014MN01819 A IN 2014MN01819A
Authority
IN
India
Prior art keywords
polymeric
disclosed
active agents
therapeutically active
backbone
Prior art date
Application number
Other languages
English (en)
Inventor
Fainaro Ronit Satchi
Ela Markovsky
COHEN Hemda BAABUR
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of IN2014MN01819A publication Critical patent/IN2014MN01819A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1819MUN2014 2012-03-05 2013-03-05 IN2014MN01819A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606557P 2012-03-05 2012-03-05
PCT/IL2013/050195 WO2013132485A1 (en) 2012-03-05 2013-03-05 Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof

Publications (1)

Publication Number Publication Date
IN2014MN01819A true IN2014MN01819A (https=) 2015-07-03

Family

ID=49116032

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1819MUN2014 IN2014MN01819A (https=) 2012-03-05 2013-03-05

Country Status (5)

Country Link
US (2) US9687562B2 (https=)
EP (1) EP2822598A4 (https=)
CN (1) CN104244988A (https=)
IN (1) IN2014MN01819A (https=)
WO (1) WO2013132485A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141826A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
EP2303288A4 (en) 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
CN102105157B (zh) 2008-05-22 2015-09-30 特拉维夫大学拉莫特有限公司 聚合物、抗血管生成剂和靶向部分的缀合物及其在制备用于治疗骨相关血管生成状况的药物中的用途
IN2014MN01819A (https=) 2012-03-05 2015-07-03 Univ Ramot
KR102135679B1 (ko) * 2013-11-19 2020-07-20 삼성전자주식회사 생분해성 폴리머를 포함하는 표적 친화성 물질 및 이의 용도
WO2016145096A1 (en) * 2015-03-09 2016-09-15 The Regents Of The University Of California Polymer-drug conjugates for combination anticancer therapy
CN105097941B (zh) * 2015-05-28 2019-02-26 京东方科技集团股份有限公司 一种薄膜晶体管及其制造方法、阵列基板、显示装置
US10478507B2 (en) 2015-10-18 2019-11-19 Ariel-University Research And Development Company Ltd. Peptide-based multiple-drug delivery vehicle
WO2017145164A1 (en) 2016-02-24 2017-08-31 Ramot At Tel-Aviv University Ltd. Polymeric conjugates and uses thereof
AU2018283383B2 (en) * 2017-06-16 2023-03-16 The Regents Of The University Of California Conjugates of active pharmaceutical ingredients
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
MX2020007306A (es) * 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
EP4137527A1 (en) 2018-12-04 2023-02-22 TIEN, Der-Yang Stereocomplexes for the delivery of anti-cancer agents
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP4045087A4 (en) * 2019-10-18 2024-03-27 University of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN111333835B (zh) * 2020-03-06 2021-11-05 同济大学 一种骨靶向聚合物、骨靶向聚合物囊泡及其制备方法与应用
AU2022415443A1 (en) * 2021-12-16 2024-07-18 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
WO2024054372A1 (en) * 2022-09-09 2024-03-14 Indiana University Research And Technology Corporation Mulitivalency for enzyme inhibition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
HUP9802675A3 (en) 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
EP1222217B1 (en) * 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
NZ520458A (en) 2000-02-24 2005-02-25 Genentech Inc Caspase activated prodrugs therapy
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
AU2003230852B2 (en) 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
AU2003226349B2 (en) 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20030217320A1 (en) 2002-05-20 2003-11-20 Gorshe Steven Scott Cyclic redundancy check circuit for use with self-synchronous scramblers
WO2004062588A2 (en) 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
DE10310082A1 (de) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
US20080193377A1 (en) 2004-06-28 2008-08-14 University Of Maryland, Baltimore Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same
CA2583315A1 (en) 2004-10-06 2006-06-01 Tiltan Pharma Ltd. Method and composition for enhancing anti-angiogenic therapy
WO2006084054A2 (en) 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
US8404650B2 (en) 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof
US8252740B2 (en) 2006-01-27 2012-08-28 The University Of Mississippi Medical Center Thermally-targeted delivery of medicaments including doxorubicin
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
CA2663375A1 (en) 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
CA2723315A1 (en) * 2008-04-30 2009-11-05 Ben-Gurion University Of The Negev Research And Development Authority Vascular delivery systems
EP2303288A4 (en) 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
WO2009141826A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
CN102105157B (zh) 2008-05-22 2015-09-30 特拉维夫大学拉莫特有限公司 聚合物、抗血管生成剂和靶向部分的缀合物及其在制备用于治疗骨相关血管生成状况的药物中的用途
IN2014MN01819A (https=) 2012-03-05 2015-07-03 Univ Ramot

Also Published As

Publication number Publication date
US20150017115A1 (en) 2015-01-15
WO2013132485A9 (en) 2014-04-10
US10155047B2 (en) 2018-12-18
US9687562B2 (en) 2017-06-27
EP2822598A1 (en) 2015-01-14
EP2822598A4 (en) 2016-04-13
WO2013132485A1 (en) 2013-09-12
US20170182176A1 (en) 2017-06-29
CN104244988A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
IN2014MN01819A (https=)
EP2563366A4 (en) USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
ZA201505813B (en) Biologically active molecules, conjugates thereof, and therapeutic uses
EP2849797A4 (en) ACTIVE CONJUGATES, CONJUGATION PROCEDURES AND USES THEREOF
NZ708171A (en) Oligonucleotide conjugates
ZA201507218B (en) Compositins and methods for modulating apolipoprotein c-iii expression
NZ710729A (en) Amatoxin derivatives
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2012106713A3 (en) Targeted nanoparticle conjugates
MX2018013623A (es) Derivados de n-acildipeptido y sus usos.
NZ708727A (en) Conjugate compounds
IN2015DN04147A (https=)
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
WO2014025681A3 (en) Devices and methods for wearable injection guides
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
EP3331573A4 (en) THERAPEUTIC CELL-INTERNALIZING CONJUGATES
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
PH12012502129A1 (en) New combination therapy in treatment of oncological and fibrotic diseases
WO2015069697A3 (en) Combination therapy
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
EP2925301A4 (en) THERAPEUTIC PRODUCT AND ANTI-CANCER IMMUNOMODULATOR DHS1P PHOTODYNAMIC
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme